Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy (BLaStM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02307058
Recruitment Status : Recruiting
First Posted : December 3, 2014
Last Update Posted : September 17, 2020
Sponsor:
Information provided by (Responsible Party):
Alan Pollack, University of Miami

Brief Summary:
The purpose of this research study is to learn about: 1) improving control of prostate cancer using an extra high dose radiation treatment to the MRI defined high risk tumor areas, in addition to the standard radiation treatment to the rest of the prostate; 2) preserving quality of life by reducing dose to the nearby organs at risk around the prostate; and 3) establishing the relationship of pre- and post-treatment MRI to MRI-directed biopsy results at 2-2.5 years after treatment.

Condition or disease Intervention/treatment Phase
Prostate Cancer Radiation: LEAD RT Radiation: HEIGHT RT Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 164 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy - The Miami BLaStM Trial
Actual Study Start Date : February 5, 2015
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: LEAD RT Group
Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
Radiation: LEAD RT
The multiparametric-MRI (MP-MRI) defined Gross Tumor Volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SV), the Clinical Target Volume (CTV)1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs may be treated to 56 Gy in 38 Fxs or full dose (CTV2), and the pelvic lymph nodes may be treated to 56 Gy in 38 Fxs (CTV3).
Other Name: Stereotactic Lattice Radiation Therapy

Experimental: HEIGHT RT Group
Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
Radiation: HEIGHT RT
The MRI defined GTV(s) will receive a higher dose per day than the CTV by dose painting. The GTV(s) will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles (CTV1) will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full dose, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
Other Name: Moderate Hypofractionation Radiation Therapy




Primary Outcome Measures :
  1. Rate of Prostate Tumor PathCR [ Time Frame: Up to 3 years ]
    Prostate Tumor Pathologic Complete Response (PathCR) will be measured using standard ultrasound guided systematic prostate biopsy.


Secondary Outcome Measures :
  1. Correlation between Pathologic Complete Response (PathCR) and Changes in serial post-RT MRIs [ Time Frame: 3 months post-RT, 9-months post-RT, within 3 months of 2-2.5 post-treatment biopsy ]
    To establish the relationship between PathCR and changes in serial post-RT MRI's obtained at 3 months and 9 months after RT, and within 3 months prior to the primary endpoint post-treatment prostate biopsy at 2.0-2.5 yr after completion of all therapy.

  2. Number of participants experiencing treatment related adverse events [ Time Frame: Up to 2 years ]
    Number of participants experiencing acute and late toxicity will be evaluated by treating physicians

  3. Health-Related Quality of Life Scores: EPIC SF-12 [ Time Frame: Up to 5.25 years (post-treatment) ]
    Health-related Quality of Life (HRQOL) will be measured using the Expanded Prostate Cancer Index Composite and Medical Outcomes Study SF-12 (EPIC SF-12) to evaluate patient function and satisfaction after prostate cancer treatment. Response options for each item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.

  4. Health-Related Quality of Life Scores: MAX-PC [ Time Frame: Up to 5.25 years (post-treatment) ]
    Health-related quality of life (HRQOL) will be measured using the scores on the Modified 18-item Memorial Anxiety Scale for Prostate Cancer (MAX-PC) from pre-treatment to post-treatment. The scale consists of 18 items (e.g. "I thought about prostate cancer even though I didn't mean to.") scored on a scale from 0 ("not at all") to 3 ("often"). Total scores range from 0 to 54, with higher scores indicating higher levels of anxiety.

  5. Health-Related Quality of Life Scores: IPSS [ Time Frame: Up to 5.25 years (post-treatment) ]
    Health-related quality of life (HRQOL) will be measured using the International Prostate Symptom Score (IPSS) to evaluate patient urinary function and quality of life. There are 7 questions related to urinary function. Responses are on a scale from 0 ("not at all") to 5 ("almost always"), with higher scores indicating higher levels of urinary dysfunction. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 ("delighted") to 6 ("terrible").

  6. Change in gene/biomarker expression [ Time Frame: Baseline, Up to 5.25 years (post-treatment) ]
    Change in gene/biomarker expression in different MP-MRI tumor regions assessed from prostate biopsy samples.

  7. Rate of participant response [ Time Frame: Up to 5.25 years (post-treatment) ]
    Participant response will be reported as the percentage of participants with reported biochemical failure (defined as having an increase of 2 ng/mL PSA levels from nadir), clinical failure (defined as having evidence of distant metastasis and overall failure), cause specific mortality and overall mortality.

  8. Change in CTC Levels [ Time Frame: Baseline (pre-treatment), Up to 2 years (post-treatment) ]
    Circulating Tumor Cell (CTC) levels evaluated from peripheral blood samples.

  9. Change in CCAF Levels [ Time Frame: Baseline (pre-treatment), Up to 2 years (post-treatment) ]
    Circulating Cancer Associated Fibroblasts (CCAF) levels evaluated from peripheral blood samples.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria:

  • A. Biopsy confirmed adenocarcinoma (including ductal) of the prostate.
  • B. T1-T3 disease based on digital rectal exam.
  • C. No evidence of metastasis by any clinical criteria or available radiographic tests (N0M0 by clinical or imaging criteria).
  • D. Gleason score 6-10.
  • E. Androgen deprivation therapy (ADT) is at the discretion of the treating physician; but, must be decided (none, short-term or long-term as counted from the luteinizing hormone-releasing hormone (LHRH) agonist or antagonist injection) prior to enrollment. An anti-androgen (e.g., bicalutamide at 50 mg per day po) is recommended to start prior to LHRH agonist injection (not recommended for LHRH antagonist injection) and is recommended to not be administered for more than 4 months. If ADT is planned, the following restrictions apply:

    • i. It may be initiated no more than 3 months prior to the signing of consent
    • ii. It must be started prior to the start of radiotherapy and
    • iii. The total length planned must be ≤ 30 months
  • F. Prostate-specific Antigen (PSA) ≤ 100 ng/mL within (+/-) 4 months of signing of consent. If PSA was above 100 and drops to ≤ 100 with antibiotics, this is acceptable for enrollment.
  • G. Subjects with T3 disease based on digital rectal exam (DRE), Gleason 8-10 or a PSA of >15 ng/ml, should have a bone scan within (+/-) 4 months of signing of consent that is without evidence of metastasis. A questionable bone scan is acceptable if additional imaging studies (e.g., plain x-rays, CT, or MRI) do not confirm for metastasis.
  • H. Suspicious peripheral zone or central gland lesion on MP-MRI

    • i. Peripheral zone: Distinct lesion on dynamic contrast-enhanced MRI (DCE-MRI) with early enhancement and later washout (Note: contrast not required for enrollment), and/or distinct lesion on the ADC map (Value <1000).
    • ii. Central gland: A suspicious central gland lesion on MP-MRI must have a distinct lesion on the apparent diffusion coefficient (ADC) map (Value <1000)
  • I. No previous pelvic radiotherapy.
  • J. No previous history of radical/total prostatectomy (suprapubic prostatectomy is acceptable).
  • K. No concurrent, active malignancy, other than nonmetastatic skin cancer or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma). If a prior malignancy is in remission for ≥ 5 years then the patient is eligible.
  • L. Ability to understand and the willingness to sign a written informed consent document.
  • M. Zubrod performance status ≤ 2. (Karnofsky or Eastern Cooperative Oncology Group (ECOG) performance status may be used to estimate Zubrod).
  • N. Willingness to fill out quality of life/psychosocial forms.
  • O. Age ≥ 35 and ≤ 85 years at signing of consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02307058


Contacts
Layout table for location contacts
Contact: Alan Pollack, MD, PhD 305-243-4916 apollack@med.miami.edu

Locations
Layout table for location information
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Alan Pollack, MD, PhD    305-243-4916    apollack@med.miami.edu   
Contact: Pavel Noa, MD    305-243-6809    pavel.noa@med.miami.edu   
Principal Investigator: Alan Pollack, MD         
Principal Investigator: Matthew Abramowitz, MD         
Sponsors and Collaborators
University of Miami
Investigators
Layout table for investigator information
Principal Investigator: Alan Pollack, MD, PhD University of Miami
Layout table for additonal information
Responsible Party: Alan Pollack, Professor, University of Miami
ClinicalTrials.gov Identifier: NCT02307058    
Other Study ID Numbers: 20140627
First Posted: December 3, 2014    Key Record Dates
Last Update Posted: September 17, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Some data after completion of the trial and publication of the primary endpoint. Additional data after publication of the secondary endpoints.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Prostatic Diseases